Ariad Pharmaceuticals Inc (NASDAQ:ARIA)’s shares are still facing the brunt of the October recall of Iclugis. The BCR-ABL tri-kinase inhibitor for adult patients of chronic or acute myelocytic (or myeloid) leukaemia was re-approved for sale under renewed labeling that cautions of its cardiovascular impacts, so that oncologists refer to it only if need be in extreme cases. That shrunk the market potential and annihilated revenue projections for the coming years. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock opened today at $7.89 and is currently trading at $8.35. The stock showed a positive weekly performance of 1.67%.
The Idera Pharmaceuticals Inc (NASDAQ:IDRA) On Mar. 13 reported its financial and operational results for the fourth quarter and year ended December 31, 2013. Net loss applicable to common stockholders for the three months ended December 31, 2013 was $6.4 million, or $0.10 per diluted share, compared to a net loss applicable to common stockholders of $6.5 million, or $0.24 per diluted share, for the same period in 2012. Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock opened at $6.16, in current trading session and currently is at $6.50, by gaining 7.26%.The 52 week range of $0.43-$6.75. Company’s market capitalization is $535.34 million.
BG Medicine, Inc. (NASDAQ:BGMD) jumps 15.2% after saying late yesterday that it has received confirmation that it is in compliance with the listing requirements of the Nasdaq Capital Market.BG Medicine, Inc. (NASDAQ:BGMD) stock is currently trading at $1.74 .The EPS of the stock is -0.66. Company’s market capitalization is $48.86 million.
Chelsea Therapeutics International Ltd.(NASDAQ:CHTP) is an interesting drug maker in mainstream biotechnology sector, which holds promise for the giant drug marketing companies such as AstraZeneca and Eli Lilly.Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) stock opened the session at $5.97, and now is at $6.20. The 52 week range of the CHTP stock remained $1.68-$6.83 and the day range was $5.95-$6.23.